Skip to main content

Market Overview

Cullinan Oncology, Inc. to Participate in the H.C. Wainwright Global Life Sciences Conference

Share:

CAMBRIDGE, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (NASDAQ:CGEM) ("Cullinan"), a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies, today announced that the company's Chief Executive Officer, Owen Hughes, will present at the upcoming H.C. Wainwright Global Life Sciences Conference.

Event: H.C. Wainwright Global Life Sciences Conference
Date: Tuesday, March 9th
Time: 7:00am EST
Location: Virtual

The presentation will be available on-demand through the H.C. Wainwright conference portal, starting at 7am EST on Tuesday, March 9th, 2021, for registered attendees only.

About Cullinan Oncology

Cullinan Oncology is a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies. The Company's strategy is to build a pipeline of therapeutic candidates that are uncorrelated across multiple dimensions, with a focus on assets that it believes have novel technology, employ differentiated mechanisms, are in a more advanced stage of development than competing candidates, or have a combination of these attributes.

Contacts:

Investor Relations
investors@cullinanoncology.com

Jeff Trigilio
+1 716.725.5019
jtrigilio@cullinanoncology.com


Primary Logo

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com